Advertisement

The Current Status of Peritoneal Surface Oncology in India

  • Aditi BhattEmail author
  • Sanket Mehta
  • Ramakrishnan Ayaloor Seshadri
Original Article
  • 6 Downloads

Abstract

With the increasing acceptance of cytoreductive surgery and HIPEC as a potentially curative treatment for primary and secondary peritoneal surface malignancies, peritoneal surface oncology has emerged as a distinct sub-specialty of surgical oncology. In the last 10 years, the acceptance of a conceptually different approach towards the management of peritoneal metastases has increased in India. During this period, over 1000 combined procedures have been performed in the country and most of the major cities have centers performing offering this treatment. Indian surgeons have formed collaborative groups to promote research and development of this specialty across the country. This article provides a detailed account of current practices pertaining to peritoneal surface oncology in the country and a future perspective.

Keywords

Peritoneal surface oncology Peritoneal metastases Cytoreductive surgery HIPEC India 

Notes

Acknowledgements

The authors thank Mr. Stephane Laurent of Capnomed, India, for providing information regarding the certified training for PIPAC.

Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Sarin R (2015) Global trends in specialist training, certification, and regulation of oncology practice and its implications for the developing world. J Cancer Res Ther 11:675–678CrossRefGoogle Scholar
  2. 2.
    India State-Level Disease Burden Initiative Collaborators (2017) Nations within a nation: variations in epidemiological transition across the states of India, 1990–2016 in the global burden of disease study. Lancet 390:2437–2460CrossRefGoogle Scholar
  3. 3.
    The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Oncol. 2018;19(10):1289–1306Google Scholar
  4. 4.
    National Cancer Registry Programme (2015) WWW page. URL: http://ncrpindia.org. Last Accessed 2018 Feb 27
  5. 5.
    Bhatt A, Goéré D (2016) Cytoreductive surgery plus HIPEC for peritoneal metastases from colorectal Cancer. Indian J Surg Oncol 7(2):177–187CrossRefGoogle Scholar
  6. 6.
    Seshadri RA, Glehen O (2016) The role of Hyperthermic intraperitoneal chemotherapy in gastric Cancer. Indian J Surg Oncol 7(2):198–207CrossRefGoogle Scholar
  7. 7.
    Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O (2014) Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg 151:347–353.  https://doi.org/10.1016/j.jviscsurg.2014.07.005 CrossRefGoogle Scholar
  8. 8.
    Bevan KE, Mohamed F, Moran BJ (2010) Pseudomyxoma peritonei. World J Gastrointest Oncol 2(1):44–50CrossRefGoogle Scholar
  9. 9.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42CrossRefGoogle Scholar
  10. 10.
    Fujimura T, Yonemura Y, Fushida S et al (1990) Continuous hyperthermic intraperitoneal perfusion for the treatment of peritoneal dissemination in gastric cancer and subsequent second-look operation. Cancer 65(1):65–71CrossRefGoogle Scholar
  11. 11.
    Yamaguchi A, Tsukioka Y, Fushida S, et al. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancer. Dis Colon RectumGoogle Scholar
  12. 12.
    Koga S, Shimizu N, Maeta M, Hamazoe R, Izumi A (1983) Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system). Gan to Kagaku Ryoho 10:358–365Google Scholar
  13. 13.
    Sayag AC, Gilly FN, Carry PY, Perdrix JP, Panteix G, Brachet A, Banssillon V, Braillon G (1993) Intraoperative chemohyperthermia in the management of digestive cancers. A general review of literature. Oncology 50(5):333–337CrossRefGoogle Scholar
  14. 14.
    Bhatt A, Mehta S, Seshadri RA, Sethna K, Zaveri S, Rajan F, Mahajan V, Singh S, Raj EH, Sugarbaker PH (2016) The initial Indian experience with Cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol 7(2):160–165CrossRefGoogle Scholar
  15. 15.
    Guidelines for import and manufacture of medical devices [Internet]. India. CDSCO. Available at: www.cdsco.nic.in/forms/ list.aspx?lid = 1580&Id = 1. Accessed 12 Nov 2018
  16. 16.
    Radhadevi N, Balamuralidhara V, Pramod Kumar TM, Ravi V (2012) Regulatory guidelines for medical devices in India: an overview. Asian J Pharm 6:10–17CrossRefGoogle Scholar
  17. 17.
    Glehen O, Mohamed F, Gilly FN (2004) Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5(4):219–228CrossRefGoogle Scholar
  18. 18.
    Veronesi U, Stafyla V (2012) Grand challenges in surgical oncology. Front Oncol 2:127. Published 2012 Oct 2.  https://doi.org/10.3389/fonc.2012.00127 Google Scholar
  19. 19.
    Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–1414.  https://doi.org/10.1002/bjs.5863 CrossRefGoogle Scholar
  20. 20.
    Kusamura S, Baratti D, Deraco M (2012) Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg 255(2):348–356.  https://doi.org/10.1097/SLA.0b013e3182436c28 CrossRefGoogle Scholar
  21. 21.
    Li Y, Yu Y, Liu Y (2014) Report on the 9th international congress on peritoneal surface malignancies. Cancer Biol Med 11(4):281–284Google Scholar
  22. 22.
  23. 23.
    Pramesh CS, Badwe RA, Borthakur BB, Chandra M, Raj EH, Kannan T, Kalwar A, Kapoor S, Malhotra H, Nayak S, Rath GK, Sagar TG, Sebastian P, Sarin R, Shanta V, Sharma SC, Shukla S, Vijayakumar M, Vijaykumar DK, Aggarwal A, Purushotham A, Sullivan R (2014) Delivery of affordable and equitable cancer care in India. Lancet Oncol 15(6):e223–e233.  https://doi.org/10.1016/S1470-2045(14)70117-2 CrossRefGoogle Scholar
  24. 24.
    Thakur J, Prinja S, Garg CC, Mendis S, Menabde N (2011) Social and economic implications of noncommunicable diseases in India. Indian J Community Med 36(suppl 1):S13–S22CrossRefGoogle Scholar
  25. 25.
    Bhatt A, Prabhu R, Sethna K, Tharayil S, Kumar M (2017) The “homemade” HIPEC [33] machine—a cost-effective alternative in low-resource countries. Pleura and Peritoneum 2:163–170CrossRefGoogle Scholar
  26. 26.
    Alyami M, Kim BJ, Villeneuve L, Vaudoyer D, Képénékian V, Bakrin N, Gilly FN, Cotte E, Glehen O, Passot G (2018) Ninety-day post-operative [34] morbidity and mortality using the National Cancer Institute’s com- Mon terminology criteria for adverse events better describe post- operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperth 34:532–537CrossRefGoogle Scholar
  27. 27.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IHJT, Ceelen WP, Pelz JO, Piso P, González-Moreno S, van der Speeten K, Morris DL (2012) Early and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456CrossRefGoogle Scholar
  28. 28.
    Villeneuve L, Passot G, Glehen O et al (2017) The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis 12:37CrossRefGoogle Scholar
  29. 29.
    Bhatt A, Mehta S, Ramakrishnan AS et al (2017) Setting up of the Indian HIPEC registry: a registry for Indian patients with peritoneal surface malignancies. Indian J Surg Oncol 8:527–532CrossRefGoogle Scholar
  30. 30.
    Sugarbaker PH (2017) The seven best from PSOGI 2016. Ann Surg Oncol 24:870–874CrossRefGoogle Scholar
  31. 31.
    Bhatt A, Mehta S, Zaveri S, Rajan F, Ray M, Sethna K, Katdare N et al (2018) Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry. Int J Hyperth.  https://doi.org/10.1080/02656736.2018.1503345
  32. 32.
    Bhatt A, Sheshadri D, Chandan G, Ramaswamy V, Pandey J, Bhorkar N, Agrawal D, Mehta S (2017) Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience. J BUON 22(1):251–257Google Scholar
  33. 33.
    Bhatt A, George A, Mehta S (2017) CRS and HIPEC for PMP-Use of the LC-CUSUM to Determine the Number of Procedures Required to Attain a Minimal Level of Proficiency in Delivering the Combined Modality Treatment. Indian J Surg Oncol 8(4):533–539.  https://doi.org/10.1007/s13193-017-0692-8 CrossRefGoogle Scholar
  34. 34.
    Gupta N, Asif S, Gandhi J, Rajpurohit S, Singh S (2017) Role of CRS and HIPEC in appendiceal and colorectal malignancies: Indian experience. Indian J Gastroenterol 36:126–130CrossRefGoogle Scholar
  35. 35.
    Somashekhar SP, Prasanna G, Jaka R, Rauthan A, Murthy HS, Karanth S (2016) Hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a single institution Indian experience. Natl Med J India 29(5):262–266Google Scholar
  36. 36.
    Bhatt A, Mishra S, Prabhu R, Ramaswamy V, George A, Bhandare S, Shah M, Mehta S (2018) Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification. Eur J Surg Oncol 44(7):1105–1111.  https://doi.org/10.1016/j.ejso.2018.03.032 CrossRefGoogle Scholar
  37. 37.
    Bhatt A, Sinukumar S, Zaveri S, Rajan F, Damodaran D, Kammar P, Mehta S (2018) A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer- A study by INDEPSO. Pleura and Peritoneum 2018; 1, Special Suppl, pp sA6–sA463.  https://doi.org/10.1515/pap-2018-7013
  38. 38.
    Pramesh CS, Badwe RA, Sinha RK (2014) The National Cancer Grid of India. Indian J Med Paediatr Oncol 35:226–227CrossRefGoogle Scholar
  39. 39.
    Katdare N, Prabhu R, Mishra S et al (2018) Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Initial Experience from Indian Centers and a Review of Literature. Indian J Surg Oncol.  https://doi.org/10.1007/s13193-018-0771-5
  40. 40.
    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical Association (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618.  https://doi.org/10.1002/cncr.25356 CrossRefGoogle Scholar
  41. 41.
    Kusamura S, Moran BJ, Sugarbaker PH, Levine EA, Elias D, Baratti D, Morris DL, Sardi A, Glehen O, Deraco M, Peritoneal Surface Oncology Group International (PSOGI) (2014) Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. Br J Surg 101(13):1758–1765.  https://doi.org/10.1002/bjs.9674 CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Surgical OncologyZydus HospitalAhmedabadIndia
  2. 2.Department of Surgical OncologySaifee HospitalMumbaiIndia
  3. 3.Department of Surgical OncologyCancer Institute, WIAChennaiIndia

Personalised recommendations